L.A. Radkevich - Dr.Sc. (Biol.), Professor, Center for Theoretical Problems of Physico-Chemical Pharmacology of the RAS E-mail: rlactp@gmail.com A.S. Kabankin - Dr.Sc. (Biol.), Leading Research Scientist, Center for Theoretical Problems of Physico-Chemical Pharma-cology of the RAS E-mail: kabankin_a@mail.ru D.A. Radkevich - Research-Engineer, Center for Theoretical Problems of Physico-Chemical Pharmacology of the RAS, Moscow E-mail: rlactp@gmail.com

By means of Spearman-s nonparametric correlation analysis interrelations between indicators of a metabolic syndrome (MS) in the various countries and incidence rates of a cancer of various localization (25 kinds) are investigated. It is established, that 68% of types of a cancer are significantly and positively associated with % of persons with Ухл1 and Ухл2 (r = 0,83-0,50); 41% of types of a cancer are associated with % of persons with IMТ1 and IMТ2 (r = 0,68-0,50); 22,7% of types of a cancer - with % of persons with COAL > 7 mmol/l (r = 0,59-0,50); 36,4% of types of a cancer - with % of persons with АД1 and АД2 (r = 0,48-0,30); 13,6% of types of a cancer - with NFA (r = 0,44-0,40). 80% of types of a cancer, and also all indicators of MS are positively associated with geographical latitude (r = 0,72-0,76). Only 18% of types of a cancer (a cancer of a nasopharynx, a liver, cervix and sarcoma Kаposi) had negative correlation with all indicators of MS and geographical latitude. By means of multiple regression analysis the influence of various indicators of MS on incidence rates of a cancer of various types is investigated. It is shown, that independent variables «% of persons with УХл1» and «% of persons with AD1» have the greatest significant influence on variability of the dependent variable. Opportunities of reduction in cancer incidence rates by regulation of various indicators of MS are discussed.

 

1. Wei X.L., Qiu M.Z., Lin H.X., Zhang Y., Liu J.X., Yu H.M., Liang W.P., Jin Y., Ren C., He M.M., Chen W.W., Luo H.Y., Wang Z.Q., Zhang D.S., Wang F.H., Li Y.H., Xu R.H. Patients with old age or proximal tumors benefit from metabolic syndrome in early stage gastric cancer // PLoS One. 2014 Mar. V. 59. № 3. R. e89965. doi: 10.1371/journal.pone.0089965. eCollection 2014.
2. Meirelles R.M. Menopause and metabolic syndrome // Arq. Bras. Endocrinol. Metabol. 2014 Mar. V. 58.  № 2. R. 91-96.
3. CHernyshova A.L., Kolomiec L.A., Bochkareva N.V., Asadchikova O.N. Metabolicheskijj sindrom, vzaimosvjaz s processami kancerogeneza ehndometrija // Sibirskijj onkologicheskijj zhurnal. 2008. № 5(29). S. 69-73.
4. Wirén S., Häggström C., Ulmer H., Manjer J., Bjørge T., Nagel G., Johansen D., Hallmans G., Engeland A., Concin H., Jonsson H., Selmer R., Tretli S., Stocks T., Stattin P. Pooled cohort study on height and risk of cancer and cancer death // Cancer Causes Control. 2014 Feb. V. 25.  № 2. R. 151-159. doi: 10.1007/s10552-013-0317-7. Epub 2013 Oct 31.
5. Nagel G., Stocks T., Späth D., Hjartåker A., Lindkvist B., Hallmans G., Jonsson H., Bjørge T., Manjer J., Häggström C., Engeland A., Ulmer H., Selmer R., Concin H., Stattin P., Schlenk R.F. Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can) // Ann Hematol. 2012 Oct. V. 91. № 10. R. 1519-1531. doi: 10.1007/s00277-012-1489-z. Epub 2012 May 16.
6. Dieli-Conwright C.M., Mortimer J.E., Schroeder E.T., Courneya K., Demark-Wahnefried W., Buchanan T.A., Tripathy D., Bernstein L. Randomized controlled trial to evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer survivors: rationale, design, and methods // BMC Cancer. 2014 Apr. V. 3. № 14. R. 238. doi: 10.1186/1471-2407-14-238.
7. World Health Organization. Global Health Observatory Data Repository. 2008.
8. International Agency for Research jn Cancer. World Health Organization. GLOBOCAN. 2008. Cancer Incidence and Mortality Worldwide in 2008.
9. Borena W., Stocks T., Jonsson H., et al. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study // Cancer Causes Controle. 2011. V. 22. № 2. P. 291-299.
10. Sang Min Park, Min Kyung Lim, Kyu Won Jung et al. Prediagnosis Smoking, Obesity, Insulin Resistence, and Second Primary Cancer Risk in Male Cancer Survivors: National Health Insurance Corporation Stady // J. Clin. Oncol. 2007. V. 25. № 30. P. 4835-4843.
11. Nikitin JU.P., Openko T.G., Simonova G.I. Metabolicheskijj sindrom i ego komponenty kak vozmozhnye modificiruemye faktory riska raka // Sibirskijj onkologicheskijj zhurnal. 2012. № 2(50). S. 69-73.
12. Häggström C., Rapp K., Stocks T., Manjer J., Bjørge T., Ulmer H., Engeland A., Almqvist M., Concin H., Selmer R., Ljungberg B., Tretli S., Nagel G., Hallmans G., Jonsson H., Stattin P. Metabolic factors associated with risk of renal cell carcinoma // PLoS One. 2013. V. 8. № 2. R. e57475. doi: 10.1371/journal.pone.0057475. Epub 2013 Feb. 28.
13. Edlinger M., Strohmaier S., Jonsson H., Bjørge T., Manjer J., Borena W.T., Häggström C., Engeland A., Tretli S., Concin H., Nagel G., Selmer R., Johansen D., Stocks T., Hallmans G., Stattin P., Ulmer H. Blood pressure and other metabolic syndrome factors and risk of brain tumour in the large population-based Me-Can cohort study // J. Hypertens. 2012 Feb. V. 30. № 2. R. 290-296. doi: 10.1097/HJH.0b013e32834e9176.
14. Häggström C., Stocks T., Ulmert D., Bjørge T., Ulmer H., Hallmans G., Manjer J., Engeland A., Nagel G., Almqvist M., Selmer R., Concin H., Tretli S., Jonsson H., Stattin P. Prospective study on metabolic factors and risk of prostate cancer // Cancer. 2012 Dec. 15. V. 118. № 24. R. 6199-6206. doi: 10.1002/cncr.27677. Epub 2012 Oct 22.
15. Piruzjan L.A., Kabankin A.S., Nikolaeva I.S., Gjulazizova K.S., Sincov A.V., Sukhinina G.P., Radkevich D.A., Radkevich L.A. Issledovanie zavisimosti onkologicheskojj zabolevaemosti v razlichnykh ehtnicheskikh populjacijakh ot geograficheskojj shiroty // Tekhnologii zhivykh sistem. 2012. № 1. S. 13-21.